Navigation Links
Human Genome Sciences Announces First Quarter 2008 Financial Results and Key Developments
Date:5/5/2008

cine to bring innovative drugs to patients with unmet medical needs.

The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon(R) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax(TM) (raxibacumab) is in late-stage development for the treatment of inhalation anthrax, and the Company is on track to begin the delivery in fall 2008 of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the U.S. Government in June 2006. Other HGS drugs in clinical development include two TRAIL receptor antibodies for the treatment of cancer. HGS1029, a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins, is expected to enter Phase 1 clinical trials for the treatment of cancer by mid-2008. In addition, HGS has substantial financial rights to three products in the GlaxoSmithKline clinical development pipeline.

For more information about HGS, please visit the Company's web site at http://www.hgsi.com. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550.

HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

SAFE HARBOR STATEMENT

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements ar
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Pioneer(R) Surgical Technology Announces First Human Implants of its NuNec(TM) Cervical Arthroplasty Device
2. China Biologic Products Announces SFDA Approval for the Production of Cryoprecipitate and for the Clinical Trial of Human Prothrombin Complex
3. Human Genome Sciences to Sponsor Conference Call to Discuss First Quarter 2008 Financial Results
4. Identity Sciences Introduces a New, Fast Forensic Human I.D. Test
5. Human Genome Sciences Advances Oncology Portfolio
6. AMDL Signs Exclusive Licensing Agreement for Human Papilloma Virus Diagnostic Test Kit in Certain Asian Countries
7. Human Pheromone Sciences Announces Quarterly and Full Year Results
8. CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve
9. Oregon Health Care Quality Corporation Receives Important Designation from U.S. Department of Health and Human Services
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Cowen Conference
11. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Lehman Brothers Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... The participants committed to not only creating unique ... time adjusting, tweaking and testing virtual models and 3D ... judging. , “I enjoyed being involved as a judge,” ... entries showed a commendable range exploring the technical capabilities ... medium and the creativity of the contestants.” , Array ...
(Date:10/1/2014)... October 01, 2014 Slone Partners ... Therapeutics, Healthcare IT, and Laboratory Testing industries, reported a ... at the director level and above from July 2013 ... stay on top of rapid breakthroughs in diagnostics, reimbursement ... diagnostic companies have been forced to fold, consolidate, or ...
(Date:9/30/2014)... German . , ... in a semiconductor layer. Quantum dots are small structures that ... a short laser pulse is fired at the photonic crystal, ... a change in the electromagnetic field around it. This change ... by the dot. As soon as the refractive index recovers ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... trends and segments with highest potential revenues Do ... Visiongain,s updated report gives you revenue predictions for ... ahead. For those therapies you find financial data, ... new analysis you get sales forecasts to 2024 ...
Breaking Biology Technology:Array Architects Challenges Staff to Create with 3D Printer 2Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2Ultrafast remote switching of light emission 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5
... Hungary, May 9 Genetic,Immunity, a US/Hungarian clinical-stage ... for targeted immune amplification, announced,today that the Company ... 5th,Annual Global Healthcare Conference to be held May ... in Monte Carlo, Monaco. The Company,s President,and Chief ...
... Pulmo BioTech Inc. (OTC,Bulletin Board: PLMO) announced today ... by 10%, taking its total holdings to 61% ... Diagnostic Technique for pulmonary,related medical conditions., Pulmo ... the Molecular,Imaging technology, developed and owned by PulmoScience, ...
... Md., May 9 Novavax, Inc. (Nasdaq:,NVAX) today announced financial ... of $7.8 million ($0.13 loss per share) for the first,quarter ... ($0.14 loss per,share) for the first quarter of 2007. Total ... million compared to $46.5 million as of,December 31, 2007. The ...
Cached Biology Technology:Genetic Immunity To Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference 2Pulmo BioTech Announces an Increase in its Stake in PulmoScience 2Pulmo BioTech Announces an Increase in its Stake in PulmoScience 3Novavax Reports First Quarter 2008 Financial Results 2Novavax Reports First Quarter 2008 Financial Results 3Novavax Reports First Quarter 2008 Financial Results 4Novavax Reports First Quarter 2008 Financial Results 5Novavax Reports First Quarter 2008 Financial Results 6Novavax Reports First Quarter 2008 Financial Results 7Novavax Reports First Quarter 2008 Financial Results 8
(Date:9/30/2014)... in urban and farm runoff in Hawaii is causing ... , The study, published Tuesday in the peer-reviewed ... the runoff ends up in algae that the turtles ... eyes, flippers and internal organs. , Scientists at Duke ... and Atmospheric Administration (NOAA) conducted the study to better ...
(Date:9/30/2014)... report that a new class of chemical compounds ... They have also pinpointed the relevant target enzyme, ... , Researchers led by LMU,s Professor Angelika ... Universitt Mnchen have identified a class of chemicals ... fight against malignant tumors. The compound is itself ...
(Date:9/30/2014)... with IVF? Here,s some hope: A new research report ... FASEB Journal , explains how scientists developed a ... which induced embryo development in human and mouse eggs ... the sperm cell during fertilization. , "We believe that ... shift in our understanding of human fertilization by providing ...
Breaking Biology News(10 mins):Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Cancer therapy: Driving cancer cells to suicide 2Synthetic sperm protein raises the chance for successful in vitro fertilization 2
... at The University of Manchester believe injections of tiny ... in the treatment of chronic lower back pain. , ... Professor Tony Freemont from The Faculty of Medical and ... and stiffen when injected into a damaged area. ...
... its new cigarette brand seems to promise a lot. "May ... boasts on its Web site, making it a natural choice ... are interested in a cigarette that responds to concerns about ... print ad for the brand, has crowed "All of the ...
... researchers have discovered a genetic cause of a mysterious ... using words. The illness, Primary Progressive Aphasia, differs from ... In PPA, a little known form of dementia, ... speech. , "This discovery, for the first ...
Cached Biology News:Swell gel could bring relief to back pain sufferers 2New cigarette designs don't offer lower predicted cancer risks 2New cigarette designs don't offer lower predicted cancer risks 3Researchers discover genetic cause for word-finding disease 2
... CoA ligase (AMP forming), Acetate thiokinase ... content. Physical form: Lyophilized powder ... reduced glutathione Preparation Unit Definition: ... S-acetyl coenzyme A from acetate, ATP and ...
... The pYD1 Yeast Display Vector is specifically ... on the surface of Saccharomyces cerevisiae. Displayed ... to interact with known or putative ligands. ... which consists of two domains Aga1 and ...
... Mut S is a member of a class ... of the DNA sequence. Mut S plays an ... DNA ,replication, in transcription-coupled nucleotide excision repair and ... bacteria. Mut S binds to DNA specifically at ...
15(S)-HEDE is produced from 11Z,14Z-eicosadienoic acid by 15-LO. 15(S)-HEDE is an inhibitor of RBL-1 cell 5-LO with an IC50 value of 26 µM....
Biology Products: